Histology and Cytology Market By Size, Share, and Forecast 2028

Summary

Report Description

Forecast Period	2024-2028
Market Size (2022)	USD 15.74 Billion
CAGR (2023-2028)	12.15%
Fastest Growing Segment	Cytology
Largest Market	North America

Market Overview

Global Histology and Cytology Market has valued at USD 15.74 Billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 12.15% through 2028. Cytology is a branch of life science concerned with the structure, function, and understanding of cells, whereas histology is concerned with the microscopic anatomy of cells and tissues of life forms. Histology and cytology strive to explain the structure of animal and plant tissues and cells, particularly at the microscopic level. Cytology is quite popular due to its rapid examination rate, precision, and affordability, as well as the high disease prevalence and use of the test for cervix screening. The diagnosis of numerous infectious and cell-based disorders, such as cervical diseases, inflammatory diseases, cancer, and autoimmune diseases, is investigated using histology and cytology. The histology and cytology market has been witnessing massive growth in the healthcare industry as a number of diseases can be diagnosed through these clinical studies. With the aid of histology and cytology, a number of infectious diseases can be identified such as cervical disease, cancer, abnormal growth, hepatitis, inflammatory diseases, diarrhea, leukemia, smallpox, rabies etc. From the commercial perspective, cytology and histology are used in the diagnostic and research procedure. The market trends are determined along with the manufacturer’s preference for the development of reagents and kits for these clinical procedures.

Key Market Drivers

Increase prevalence of cancer

The prevalence of cancer can have a significant influence on the growth of the Global Histology and Cytology Market. Histology and cytology are branches of medical science that involve the study of cells and tissues, often used in diagnosing and understanding various diseases, including cancer. With an increasing number of cancer cases, the demand for accurate and early diagnostic techniques becomes crucial. Histology and cytology play a pivotal role in diagnosing different types of cancers by examining tissue samples and cells under a microscope. As more individuals seek cancer screening and diagnostic services, the demand for histology and cytology services and equipment rises. The growing prevalence of cancer drives the need for more sophisticated diagnostic technologies. Advances in digital pathology, automation, and imaging technologies have improved the accuracy and efficiency of histology and cytology processes. This leads to increased adoption of these advanced technologies, contributing to market growth. As cancer rates rise, there is a heightened emphasis on research and development efforts to understand the disease better and develop targeted therapies. Histology and cytology techniques are essential for researchers to study cancer tissues at a microscopic level, aiding in the development of personalized treatment strategies. This drives demand for histology and cytology tools, equipment, and services. Biopsy procedures involve the removal of a sample of tissue for examination. With the increasing prevalence of cancer, the number of biopsy procedures also increases. Histology and cytology play a critical role in analyzing these biopsy samples to determine the presence, type, and stage of cancer, leading to higher demand for related services and equipment. According to the World Health Organization Updates in February 2022, Cervical cancer is the fourth most common cancer in women worldwide, with 604,000 new cases and 342,000 deaths by 2020.

Increasing research and development activities

R&D efforts lead to the development of innovative technologies, equipment, and methodologies in the field of histology and cytology. These advancements improve the accuracy, efficiency, and reliability of diagnostic and research processes. New imaging techniques, automation solutions, and digital pathology systems developed through R&D contribute to the growth of the market by offering improved diagnostic capabilities. R&D activities focus on improving the accuracy of histology and cytology techniques in identifying various diseases, including cancer. The development of novel staining methods, molecular markers, and advanced imaging technologies enables pathologists and researchers to identify subtle changes in cells and tissues, leading to more accurate diagnoses. This increased accuracy drives the demand for these services and tools. Histology and cytology are crucial in drug development and the discovery of targeted therapies. R&D activities in these fields help researchers understand how specific drugs interact with cancer cells and tissues at a microscopic level. This knowledge is essential for developing new therapeutic agents that effectively target cancer cells while minimizing damage to healthy tissue. R&D activities contribute to the automation and digitalization of histology and cytology processes. Automated systems for tissue processing, staining, and slide analysis reduce human errors and increase efficiency. Digital pathology solutions enable remote diagnosis, collaboration, and data sharing, which is especially valuable in research and clinical settings. These advancements promote market growth by streamlining workflows and improving productivity. According to the American Cancer Society’s report in 2022 over 1.9 million new cancer cases are expected to be diagnosed in the United States in 2022. and additionally, 80% of the people diagnosed with cancer in the United States are 55 years of age or older and 57% are 65 or older.

Growing Focus on Personalized Medicine

Personalized medicine relies heavily on molecular diagnostics, which involve analyzing genetic and molecular information from patient samples. Histology and cytology techniques are essential for extracting and analyzing these molecular markers, allowing clinicians to identify specific genetic mutations and alterations that guide treatment decisions. This increased demand for molecular diagnostics drives growth in the histology and cytology market. Personalized medicine requires a comprehensive understanding of a patient's disease at the cellular and molecular levels. Histology and cytology techniques enable pathologists and researchers to analyze tissues and cells in detail, providing critical insights into the genetic and molecular characteristics of a patient's condition. This information is crucial for tailoring treatment strategies and selecting the most effective therapies. Histology and cytology play a pivotal role in the development of targeted therapies. Personalized medicine aims to identify specific biomarkers and genetic alterations associated with particular diseases. Histology and cytology techniques allow researchers to identify these markers, enabling the development of drugs that target the specific molecular characteristics of a patient's disease. This drives the demand for histological and cytological analysis in drug discovery and development. Personalized medicine relies on the integration of various data sources, including clinical, genetic, and imaging data. Digital pathology, which involves the digital capture and analysis of histology images, facilitates the integration of these data types. It enables pathologists and researchers to collaborate remotely, share insights, and make informed decisions based on a comprehensive dataset. Histology and cytology techniques are essential for analyzing tissue and cell samples to identify biomarkers that are indicative of disease presence, progression, and response to treatment. In personalized medicine, biomarkers guide treatment decisions by providing insights into a patient's unique disease characteristics, fostering the need for advanced histological and cytological analysis.

Download Free Sample Report

Key Market Challenges

Technological Complexity and Costs

Advanced histology and cytology technologies often require significant upfront investments in terms of equipment, software, training, and infrastructure. This can be a barrier for smaller clinics, hospitals, and research facilities with limited financial resources. The high initial investment can lead to slower adoption rates, especially in regions with budget constraints. Utilizing complex histology and cytology technologies requires a skilled workforce with specialized training. Training pathologists, technicians, and clinicians to effectively use and interpret data from these technologies can be time-consuming and costly. The scarcity of skilled personnel can further impede technology adoption. Technologically advanced equipment typically requires regular maintenance and updates to ensure optimal performance. The costs associated with maintenance, repairs, and software updates can add to the overall expenses for healthcare institutions. This ongoing financial commitment can be a deterrent, particularly for smaller facilities. Integrating new technology into existing healthcare systems and workflows can be challenging. Compatibility issues with existing systems and processes may arise, requiring additional investments in software development and integration solutions. These challenges can delay technology implementation and adoption.

Laboratory Workforce Shortages

A shortage of laboratory professionals, such as pathologists and histotechnologists, can lead to delays in diagnosing and reporting test results. This can prolong patient care and treatment decisions, impacting patient outcomes and satisfaction. With fewer skilled professionals available, laboratories may struggle to handle a high volume of samples efficiently. This reduced capacity can lead to longer turnaround times for tests, causing frustration among healthcare providers and patients. Complex histology and cytology technologies often require specialized training to operate effectively. A shortage of skilled professionals who can use these technologies can result in underutilization of expensive equipment and software, hindering the return on investment for healthcare institutions. Skilled laboratory professionals contribute to research, innovation, and the development of new diagnostic techniques. Workforce shortages can limit the capacity for innovation, slowing down the introduction of new technologies to the market. Attracting and retaining skilled laboratory professionals becomes difficult when shortages exist. Competitive job markets and inadequate compensation can deter individuals from pursuing careers in histology and cytology. Workforce shortages might be more pronounced in certain regions or healthcare settings, leading to uneven access to histology and cytology services. This can result in disparities in healthcare quality and patient outcomes. A shortage of laboratory professionals can impact educational programs and training initiatives. The lack of qualified educators and mentors can lead to gaps in training for new professionals, perpetuating the workforce shortage.

Key Market Trends

Liquid Biopsies and Circulating Biomarkers

Liquid biopsies involve the analysis of biomarkers, such as circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs), present in blood or other bodily fluids. They enable early detection of diseases, including cancer, even before traditional symptoms manifest. This capability drives the demand for histology and cytology services that can identify and analyze these biomarkers accurately. Unlike traditional tissue biopsies, which require invasive procedures, liquid biopsies are minimally invasive. This approach reduces patient discomfort, risk, and recovery time. As liquid biopsies gain prominence, the demand for traditional histological and cytological procedures might decline for certain applications, but histology and cytology techniques are still essential for validating liquid biopsy results and providing comprehensive diagnoses. Liquid biopsies are often used in conjunction with traditional histology and cytology techniques. They can provide additional information about tumor heterogeneity, genetic mutations, and treatment responses that might not be apparent through tissue biopsies alone. The integration of liquid biopsy data enhances the overall diagnostic accuracy and treatment decision-making process. Circulating biomarkers provide valuable information about a patient's tumor characteristics, enabling the development of personalized treatment strategies. This demand for personalized medicine supports the growth of the histology and cytology market, as these techniques remain essential for understanding tissue-level details and providing comprehensive patient care.

Multi-Omics Approaches

Multi-omics approaches enable researchers to study diseases, including cancer, at multiple levels simultaneously. This comprehensive view provides insights into the molecular mechanisms underlying disease development, progression, and treatment response. The demand for histology and cytology techniques increases as they play a key role in validating findings from multi-omics data and providing tissue-specific context. Multi-omics approaches facilitate the identification of novel biomarkers associated with diseases. These biomarkers can be used for early detection, diagnosis, and prognosis. Histology and cytology techniques are essential for validating the presence and significance of these biomarkers in tissue samples, supporting their translation into clinical practice. Multi-omics approaches aid in drug discovery by identifying potential drug targets and understanding how drugs interact with biological systems. Histology and cytology techniques play a role in confirming the effects of drugs on tissue morphology and structure, helping validate findings from multi-omics studies. Multi-omics approaches offer insights into complex molecular pathways and networks involved in diseases. Histology and cytology techniques provide spatial information that complements the functional insights from multi-omics data, leading to a more holistic understanding of disease mechanisms.

Segmental Insights

Type of Examination Insights

Based on the Type of Examination, the cytology segment is anticipated to witness substantial market growth throughout the forecast period. This growth can be attributed to growing demand for Cytology techniques, such as Pap smears and fine-needle aspirations, are crucial for the early detection of diseases, particularly cancer. These methods allow for the identification of abnormal cellular changes before they manifest as larger tissue-level anomalies. Early detection enables timely interventions and significantly improves patient outcomes. Cytology plays a pivotal role in cancer screening and diagnosis. Techniques like Pap smears, which examine cervical cells for signs of pre-cancerous or cancerous changes, have been instrumental in reducing cervical cancer incidence. Additionally, cytological examination of bodily fluids like sputum, urine, and pleural fluid aids in detecting cancers affecting various organs.

Application Insights

Based on the application segment, the Drug Discovery & Designing segment has been the dominant force in the market. The Drug discovery begins with identifying and validating potential therapeutic targets, often involving specific molecules or pathways implicated in diseases. Histology and cytology techniques provide insights into the expression, localization, and activity of these targets within tissues and cells, helping researchers select viable candidates for drug development. Before new drugs can progress to clinical trials, their safety and potential toxicity need to be assessed. Histology and cytology techniques enable researchers to examine the effects of drug candidates on various tissues and organs, helping identify potential adverse effects. As drug discovery becomes more targeted and personalized, companion diagnostics that involve histological and cytological analyses can identify patients who are likely to benefit from specific drugs. This trend increases the demand for histology and cytology services.

Download Free Sample Report

Regional Insights

North America, specifically the Histology and Cytology Market, dominated the market in 2022, primarily due to North America, particularly the United States and Canada, boasts well-developed healthcare systems with advanced facilities and technologies. This infrastructure provides a conducive environment for the adoption of cutting-edge histology and cytology techniques and technologies. North America is home to many leading research institutions, academic centers, and pharmaceutical companies. These organizations actively engage in research and development activities related to histology, cytology, and various medical technologies. The concentration of research efforts fuels innovation and drives the growth of the market. North America has a robust regulatory framework for medical devices, diagnostics, and healthcare services. A clear regulatory environment encourages the development and adoption of new technologies, ensuring patient safety and quality standards.

Recent Developments

In April 2023, Danaher’s Leica Biosystems announced the U.S. FDA clearance for its Bond MMR Antibody Panel, which offers a high-performing immunohistochemistry (IHC) mismatch repair (MMR) opportunity for clients that are screening colorectal cancer (CRC) individuals for probable Lynch syndrome.
In July 2022, Nanostics Inc launched a prospective clinical study designed to validate a novel and minimally invasive bladder cancer diagnostic test, Clarity DX Bladder using its Clarity DX diagnostic platform.
In June 2022, The Fine Needle Aspiration Cytology (FNAC) test facility has been launched at the Almora Medical College. This test helps in the detection of chronic diseases like cancer, at an early stage.

Key Market Players

Hologic, Inc.
F Hoffmann-La Roche AG.
Abbott Laboratories Inc.
Becton Dickinson & Co.
Danaher Corporation.
Merck KGaA.
Thermo Fisher Scientific, Inc.
Sysmex Corporation.
Trivitron Healthcare.
Koninklijke Philips N.V.

By Type of Examination

By Product

By Application

By Region

Histology

Cytology

Instruments and Analysis Software System

Consumable and Reagents

Drug Discovery & Designing

Clinical Diagnostics

Research

North America

Europe

Asia Pacific

South America

Middle East & Africa

Report Scope:

In this report, the Global Histology and Cytology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

· Histology and Cytology Market, By Type of Examination:

o Histology

o Cytology

· Histology and Cytology Market, By Product:

o Instruments and Analysis Software System

o Consumable and Reagents

· Histology and Cytology Market, By Application:

o Drug Discovery & Designing

o Clinical Diagnostics

o Research

· Histology and Cytology Market, By Region:

o North America

§ United States

§ Canada

§ Mexico

o Europe

§ France

§ United Kingdom

§ Italy

§ Germany

§ Spain

o Asia-Pacific

§ China

§ India

§ Japan

§ Australia

§ South Korea

o South America

§ Brazil

§ Argentina

§ Colombia

o Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

§ Kuwait

§ Turkey

§ Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Histology and Cytology Market.

Available Customizations:

Global Histology and Cytology market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Histology and Cytology Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Histology and Cytology Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Type Of Examination (Histology, Cytology)

5.2.2. By Product (Instruments and Analysis Software System, Consumable and Reagents)

5.2.3. By Application (Drug Discovery & Designing, Clinical Diagnostics, Research)

5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)

5.2.5. By Company (2022)

5.3. Market Map

5.3.1 By Type of Examination

5.3.2 By Product

5.3.3 By Application

5.3.4 By Region

6. North America Histology and Cytology Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Type Of Examination (Histology, Cytology)

6.2.2. By Product (Instruments and Analysis Software System, Consumable and Reagents)

6.2.3. By Application (Drug Discovery & Designing, Clinical Diagnostics, Research)

6.2.4. By Country

6.3. North America: Country Analysis

6.3.1. United States Histology and Cytology Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Type of Examination

6.3.1.2.2. By Product

6.3.1.2.3. By Application

6.3.2. Canada Histology and Cytology Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Type of Examination

6.3.2.2.2. By Product

6.3.2.2.3. By Application

6.3.3. Mexico Histology and Cytology Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Type of Examination

6.3.3.2.2. By Product

6.3.3.2.3. By Application

7. Europe Histology and Cytology Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Type Of Examination (Histology, Cytology)

7.2.2. By Product (Instruments and Analysis Software System, Consumable and Reagents)

7.2.3. By Application (Drug Discovery & Designing, Clinical Diagnostics, Research)

7.2.4. By Country

7.3. Europe: Country Analysis

7.3.1. France Histology and Cytology Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Type of Examination

7.3.1.2.2. By Product

7.3.1.2.3. By Application

7.3.2. Germany Histology and Cytology Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Type of Examination

7.3.2.2.2. By Product

7.3.2.2.3. By Application

7.3.3. United Kingdom Histology and Cytology Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Type of Examination

7.3.3.2.2. By Product

7.3.3.2.3. By Application

7.3.4. Italy Histology and Cytology Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Type of Examination

7.3.4.2.2. By Product

7.3.4.2.3. By Application

7.3.5. Spain Histology and Cytology Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Type of Examination

7.3.5.2.2. By Product

7.3.5.2.3. By Application

8. Asia-Pacific Histology and Cytology Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Type Of Examination (Histology, Cytology)

8.2.2. By Product (Instruments and Analysis Software System, Consumable and Reagents)

8.2.3. By Application (Drug Discovery & Designing, Clinical Diagnostics, Research)

8.2.4. By Country

8.3. Asia-Pacific: Country Analysis

8.3.1. China Histology and Cytology Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Type of Examination

8.3.1.2.2. By Product

8.3.1.2.3. By Application

8.3.2. India Histology and Cytology Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Type of Examination

8.3.2.2.2. By Product

8.3.2.2.3. By Application

8.3.3. Japan Histology and Cytology Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Type of Examination

8.3.3.2.2. By Product

8.3.3.2.3. By Application

8.3.4. South Korea Histology and Cytology Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Type of Examination

8.3.4.2.2. By Product

8.3.4.2.3. By Application

8.3.5. Australia Histology and Cytology Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Type of Examination

8.3.5.2.2. By Product

8.3.5.2.3. By Application

9. South America Histology and Cytology Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Type Of Examination (Histology, Cytology)

9.2.2. By Product (Instruments and Analysis Software System, Consumable and Reagents)

9.2.3. By Application (Drug Discovery & Designing, Clinical Diagnostics, Research)

9.2.4. By Country

9.3. South America: Country Analysis

9.3.1. Brazil Histology and Cytology Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Type of Examination

9.3.1.2.2. By Product

9.3.1.2.3. By Application

9.3.2. Argentina Histology and Cytology Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Type of Examination

9.3.2.2.2. By Product

9.3.2.2.3. By Application

9.3.3. Colombia Histology and Cytology Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Type of Examination

9.3.3.2.2. By Product

9.3.3.2.3. By Application

10. Middle East and Africa Histology and Cytology Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Type Of Examination (Histology, Cytology)

10.2.2. By Product (Instruments and Analysis Software System, Consumable and Reagents)

10.2.3. By Application (Drug Discovery & Designing, Clinical Diagnostics, Research)

10.2.4. By Country

10.3. MEA: Country Analysis

10.3.1. South Africa Histology and Cytology Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Type of Examination

10.3.1.2.2. By Product

10.3.1.2.3. By Application

10.3.2. Saudi Arabia Histology and Cytology Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Drug Type

10.3.2.2.2. By Type of Examination

10.3.2.2.3. By Product

10.3.2.2.4. By Application

10.3.3. UAE Histology and Cytology Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Type of Examination

10.3.3.2.2. By Product

10.3.3.2.3. By Application

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development

12.2. Mergers & Acquisitions

12.3. Product Launches

13. Global Histology And Cytology Market: SWOT Analysis

14. Porter’s Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Business Overview

15.2. Product Offerings

15.3. Recent Developments

15.4. Financials (As Reported)

15.5. Key Personnel

15.6. SWOT Analysis

15.6.1 Hologic, Inc.

15.6.2 F Hoffmann-La Roche AG.

15.6.3 Abbott Laboratories Inc.

15.6.4 Becton Dickinson & Co.

15.6.5 Danaher Corporation.

15.6.6 Merck KGaA.

15.6.7 Thermo Fisher Scientific, Inc.

15.6.8 Sysmex Corporation.

15.6.9 Trivitron Healthcare.

15.6.10 Koninklijke Philips N.V.

16. Strategic Recommendations

Figures and Tables

Frequently asked questions

What was the market size of the Global Histology and Cytology Market in 2022?

The market size of the Global Histology and Cytology Market was estimated to be USD 15.74 Billion in 2022.

Which was the dominant segment by application in the Global Histology and Cytology Market in 2022?

The drug discovery and designing segment demonstrated significant dominance in 2022, primarily driven by the widespread use of histomorphometry and IHC staining in biotechnology and pharmaceutical companies for drug development. The image analysis is applied across several steps of drug discovery & development such as drug efficacy & safety studies, target validation, drug repositioning, patient stratification, and biomarker expression studies.

Which is the dominant region in the Global Histology and Cytology Market?

North America emerged as the dominant market in 2022, capturing a significant revenue share. The region's market growth is propelled by high incidences of cancer, extensive R&D activities, the presence of key players, and an established research infrastructure for pathology services. In addition, the high rate of product approval and commercialization in the region is further contributing to the growth of the market for histology and cytology.

What are the major drivers for the Global Histology and Cytology Market?

Increasing prevalence of cell-based diseases such as cancer and rising demand for the detection of tissue and cell characteristics are the major drivers for the Global Histology and Cytology Market.

Related Reports

Sakshi Bajaal

Business Consultant

Talk To Analyst

Press Release

Histology and Cytology Market to grow with a CAGR of 12.15% through 2028

Nov, 2023

The increasing prevalence of cancer is expected to drive the Global Histology and Cytology Market growth in the forecast period, 2024-2028.

Buy Now